These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8224164)

  • 1. The gag precursor contains a specific HIV-1 protease cleavage site between the NC (P7) and P1 proteins.
    Wondrak EM; Louis JM; de Rocquigny H; Chermann JC; Roques BP
    FEBS Lett; 1993 Oct; 333(1-2):21-4. PubMed ID: 8224164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
    Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
    Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
    Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
    J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended nucleocapsid protein is cleaved from the Gag-Pol precursor of human immunodeficiency virus type 1.
    Chen N; Morag A; Almog N; Blumenzweig I; Dreazin O; Kotler M
    J Gen Virol; 2001 Mar; 82(Pt 3):581-590. PubMed ID: 11172099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro processing of HIV-1 nucleocapsid protein by the viral proteinase: effects of amino acid substitutions at the scissile bond in the proximal zinc finger sequence.
    Tözsér J; Shulenin S; Louis JM; Copeland TD; Oroszlan S
    Biochemistry; 2004 Apr; 43(14):4304-12. PubMed ID: 15065874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
    Bally F; Martinez R; Peters S; Sudre P; Telenti A
    AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.
    Pettit SC; Henderson GJ; Schiffer CA; Swanstrom R
    J Virol; 2002 Oct; 76(20):10226-33. PubMed ID: 12239298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cleavage of p15 protein in vitro by human immunodeficiency virus type 1 protease is RNA dependent.
    Sheng N; Erickson-Viitanen S
    J Virol; 1994 Oct; 68(10):6207-14. PubMed ID: 8083960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein.
    Tritch RJ; Cheng YE; Yin FH; Erickson-Viitanen S
    J Virol; 1991 Feb; 65(2):922-30. PubMed ID: 1987379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
    Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
    J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles.
    Turpin JA; Terpening SJ; Schaeffer CA; Yu G; Glover CJ; Felsted RL; Sausville EA; Rice WG
    J Virol; 1996 Sep; 70(9):6180-9. PubMed ID: 8709244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.
    Carrillo A; Stewart KD; Sham HL; Norbeck DW; Kohlbrenner WE; Leonard JM; Kempf DJ; Molla A
    J Virol; 1998 Sep; 72(9):7532-41. PubMed ID: 9696850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of intracellular human immunodeficiency virus type-1 protease activity.
    Gatlin J; Arrigo SJ; Schmidt MG
    Virology; 1998 Apr; 244(1):87-96. PubMed ID: 9581782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of capsid sequence and immature nucleocapsid proteins p9 and p15 in Human Immunodeficiency Virus type 1 genomic RNA dimerization.
    Kafaie J; Dolatshahi M; Ajamian L; Song R; Mouland AJ; Rouiller I; Laughrea M
    Virology; 2009 Mar; 385(1):233-44. PubMed ID: 19070880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
    Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
    Towler EM; Gulnik SV; Bhat TN; Xie D; Gustschina E; Sumpter TR; Robertson N; Jones C; Sauter M; Mueller-Lantzsch N; Debouck C; Erickson JW
    Biochemistry; 1998 Dec; 37(49):17137-44. PubMed ID: 9860826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.
    Accola MA; Strack B; Göttlinger HG
    J Virol; 2000 Jun; 74(12):5395-402. PubMed ID: 10823843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope mapping of a monoclonal antibody which binds HIV-1 Gag and not the Gag-derived proteins.
    Sarubbi E; Denaro M
    FEBS Lett; 1993 Dec; 335(3):335-7. PubMed ID: 7505237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.